Orsini Specialty Pharmacy Selected as part of the Limited Specialty Pharmacy Network For VYJUVEK™, the First Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
ELK GROVE VILLAGE, Ill., May 23, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Krystal Biotech has selected it as part of the limited specialty pharmacy network for VYJUVEK™ (beremagene geperpavec-svdt), a topical gene therapy for the treatment of Dystrophic Epidermolysis Bullosa (DEB).
- ELK GROVE VILLAGE, Ill., May 23, 2023 /PRNewswire/ -- Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Krystal Biotech has selected it as part of the limited specialty pharmacy network for VYJUVEK™ (beremagene geperpavec-svdt), a topical gene therapy for the treatment of Dystrophic Epidermolysis Bullosa (DEB).
- For more information about VYJUVEK, see the Full Prescribing Information or https://vyjuvek.com .
- DEB is caused by mutations in the COL7A1 gene that affects the skin and mucosal tissues.
- "Orsini Specialty Pharmacy is deeply committed to helping DEB patients and their families gain access to this revolutionary treatment and provide ongoing support in managing their condition."